ReviewBiotechnology and applied biochemistry2025
Escherichia coli in the production of biopharmaceuticals.
Review in Biotechnology and applied biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Impact of Organic Solvents, Surfactants, and Nonfunctionalized PEGs on PEGylation Reaction Yield.ACS omega · 2026Article
- Feathered bioreactor: transforming a chicken egg into a recombinant protein biomanufacturing foundry.Poultry science · 2026Review
- Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Overcoming challenges in the production of a human-like L-asparaginase: advanced strategies for expression and purification.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- Biological Profiling of Postbiotics of Lactobacillus plantarum: Antibacterial, Antioxidant, and Cytotoxic Properties Under In Vitro and Food Circumstances.Probiotics and antimicrobial proteins · 2026Article
- ColiFormer: A Transformer-Based Codon Optimization Model Balancing Multiple Objectives for EnhancedBioengineering (Basel, Switzerland) · 2026Article
- Nanobodies in biomedicine: from molecular characteristics to fabrication and clinical translation.Military Medical Research · 2026Review
- Optimization of thrombopoietin mimetic peptide fusion proteins with albumin-binding domain for enhanced bioactivity and extended half-life.Scientific reports · 2025Article
- A novel IgG-Fc-Fused multiepitope vaccine against Brucella: robust immunogenicity.Microbial cell factories · 2025Article
- Escherichia coli in the production of biopharmaceuticals.Biotechnology and applied biochemistry · 2025Review
- EngineeredInternational journal of nanomedicine · 2025Article
- Bicistronic Vector Expression of Recombinant Jararhagin-C and Its Effects on Endothelial Cells.Toxins · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes. After insulin, many biopharmaceuticals produced from E. coli have been approved by the US Food and Drug Administration and the European Medicines Agency to treat various human diseases. Although E. coli has some disadvantages, such as lack of post-translational modifications and toxicity, it is an important host with advantages such as being a well-known bacterium in recombinant protein production, cheap, simple production system, and high yield. This study examined biopharmaceuticals produced and approved in E. coli under the headings of peptides, hormones, enzymes, fusion proteins, antibody fragments, vaccines, and other pharmaceuticals. The topics on which these biopharmaceuticals were approved for treating human diseases, when and by which company they were produced, and their use and development in the field are included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.